Clin2
NCT07722546Possibly a fitRecruiting

Felzartamab for Graves' disease in adults

Graves' Disease

Treatments studied

Part of Eyes & vision, Hormones & metabolism, Immune system & allergy clinical trials.

This study tests an investigational drug called felzartamab to see if it can help control thyroid function in adults with Graves' disease. It may offer a new option if you are still having symptoms despite anti-thyroid medication.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
60 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You have active Graves' disease with positive thyroid antibodies (TRAb), and your thyroid hormone levels are in the normal range while your TSH is low.
  • You are currently on a stable dose of anti-thyroid drugs (like methimazole) for at least 12 weeks.
  • You have not had your thyroid removed or received radioactive iodine therapy.
  • You do not have severe or active thyroid eye disease that needs treatment.
  • You are not taking any strong immune-suppressing medications for other autoimmune diseases.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07570316Recruiting· Phase 3
Testing efgartigimod for Graves' disease hyperthyroidism

This study tests whether efgartigimod, an injectable medication given under the skin, can help control overactive thyroid (Graves' disease) in adults already taking methimazole or carbimazole. The goal is to see if it reduces thyroid antibodies and improves thyroid hormone levels.

Orange, California
NCT07305818Recruiting· Phase 1
Testing a new drug for Graves' disease

This study tests a new medication called MER511 for adults with Graves' disease. The goal is to see if it is safe and how it works when taken once or multiple times.

Torrance, California
NCT07596849Recruiting· Phase 3
Testing a New Injection for Graves' Disease

This study tests efgartigimod, a new medicine given by injection under the skin, to see if it can help control Graves' disease (an overactive thyroid condition). The goal is to reduce the need for other thyroid medications or help people stop taking them.

Surrey
NCT07661056Recruiting· Phase 3
Investigational drug for treating graves' disease overactive thyroid

This study tests a new medicine, BHV-1300, to see if it can safely and effectively reduce the overactive thyroid caused by Graves' disease, an autoimmune condition. It may offer a new option for people who haven't had certain prior treatments.

Tucson, Arizona
NCT07333677Recruiting· Early Phase 1
Testing CAR-T therapy for severe graves' disease

This early-phase trial tests a new type of treatment called CAR-T cells (special immune cells made in a lab) to target and calm down the overactive immune system in people with severe Graves' disease that hasn't improved with standard medicines. It may offer a new option for those who have been on treatment for years or have had multiple relapses.

Shanghai, Shanghai Municipality
NCT06068179Recruiting· Phase 2/Phase 3
Can a new combo help Graves' disease go into remission?

This trial tests a combination of two medicines (methimazole and mycophenolate) to see if they can help people with newly diagnosed Graves' disease go into remission faster and more safely. If you are newly diagnosed and haven't had treatment yet, this study might offer a way to get better control of your condition.

Xiamen, Fujian

Hear when a new Graves Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.